Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that its new drug application for sacituzumab tirumotecan, a treatment for advanced non-small cell lung cancer, has been accepted by China’s National Medical Products Administration. This drug, showing promising results in clinical trials, targets solid tumors and has been prioritized for review. The company has licensed rights to commercialize the drug outside Greater China to Merck & Co., Inc.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.